Academic Highlights: Preventing Clinical Deterioration in the Course of Schizophrenia: The Potential for Neuroprotection. [CME]
J Clin Psychiatry 2006;67(6):983-990
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Click to enlarge page
Jeffrey A. Lieberman, M.D., opened with a brief overview of the natural history of schizophrenia. When Emil Kraepelin1 initially distinguished dementia praecox, which later came to be known as schizophrenia, from general insanity, he did so based not on patients’ symptoms or on any particular aspect of the clinical presentation but on the longitudinal course of the illness, particularly the clinical deterioration that was noticed in patients. Patients with schizophrenia in the early part of the twentieth century, when Kraepelin was performing his research, had no treatment available to them and thus were forced to suffer the consequences of their illness.